{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457820597
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = zu/o
| target = [[CD62L]]
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 395639-53-9
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}
'''Aselizumab''' is an [[immunosuppressive drug]] which has been investigated for the use in severely injured patients. It binds to [[CD62L]].<ref>{{cite journal|pmid=15483410|year=2004|last1=Seekamp|first1=A|last2=Van Griensven|last3=Dhondt|last4=Diefenbeck|last5=Demeyer|last6=Vundelinckx|last7=Haas|last8=Schaechinger|last9=Wolowicka|title=The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial|volume=32|issue=10|pages=2021â€“8|journal=Critical Care Medicine|doi=10.1097/01.CCM.0000142396.59236.F3|first2=M|first3=E|first4=M|first5=I|first6=G|first7=N|first8=U|first9=L|last10=Rammelt|first10=Stefan|last11=Stroobants|first11=Jan|last12=Marzi|first12=Ingo|last13=Brambrink|first13=Ansgar M.|last14=Dziurdzik|first14=Piotr|last15=Gasiorowski|first15=Jacek|last16=Redl|first16=Heinz|last17=Beckert|first17=Michael|last18=Khan-Boluki|first18=Jasmin|display-authors=8}}</ref>

==References==
{{reflist}}

{{immunosuppressants}}
{{Monoclonals for immune system}}

[[Category:Monoclonal antibodies]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}